If you had invested in Novavax (NASDAQ: NVAX) at the beginning of 2020, you'd be sitting pretty right now. Novavax's efforts to develop and market a vaccine for COVID-19 explain the company's terrific performance of late. The company's average price target of $264.20 implies gains of 93% from its share price of $136.86 as of this writing.
A South African court on Tuesday threw out former president Jacob Zuma's bid to remove the chief prosecutor in his long-running corruption trial over a 1990s arms deal.
The new rules, to be announced in Parliament, will boost the prospects of the £20bn project in Suffolk.